FDA Clears Teleflex Needles - Analyst Blog
January 28 2013 - 7:00AM
Zacks
Teleflex
Incorporated (TFX) has obtained the approval of the U.S.
Food and Drug Administration (FDA) for its Arrow UltraQuick
peripheral nerve block (PNB) needles. The UltraQuik needles enhance
block success for single-injection PNBs using the ultrasound
approach.
This needle, along with the
StimuQuick and StimuQuick Echo needles from the Anesthesia and
Respiratory division under the larger Critical Care unit, provides
a wide range of clinical solutions for performing PNBs. The
company’s anesthetic and respiratory product lines are contributing
positively to the growth of the Critical Care business, which grew
by 4.5% on a constant currency basis in the last reported
quarter.
Teleflex has embarked on enhancing
its Arrow brand ever since the acquisition of Arrow International
in 2007. The acquisition has significantly bolstered single-use
product offerings for critical care from Teleflex and expanded its
global reach.
Limerick, Pennsylvania-based
Teleflex is a global leader in medical devices used in critical
care and surgery. The company focuses on profitable and consistent
growth and is expected to yield results. The company envisages its
sales growth to surpass the market growth. It also plans to gain
market share in key product areas.
Product innovation is the driving
force for Teleflex. Contributions from new products in the most
recent quarter reflect gains from the company’s increased focus on
research and development. However, the failure to protect its
intellectual property and lower-than-expected market adoption of
the new products may hinder its growth.
Teleflex operates in a highly
competitive medical devices industry and the implementation of the
medical devices tax from this year is likely to put additional
pressure on its bottom line. Further, the company operates in a
stringent regulatory environment. The demand for its products is
susceptible to healthcare reimbursement systems in the domestic as
well as the international market.
The stock carries a Zacks Rank #3
(Hold). Medical instrument companies, such as Cantel
Medical Corp. (CMN), Delcath Systems,
Inc. (DCTH) and Cyberonics Inc. (CYBX) with Zacks
Rank #1 (Strong Buy), are expected to do well.
CANTEL MED CORP (CMN): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
TELEFLEX INC (TFX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jul 2023 to Jul 2024